Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 18, 2024 08:54 ET | Source: G1 Therapeutics

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer

Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
September 05, 2024 06:30 ET | Source: G1 Therapeutics

Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period

Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
August 08, 2024 06:30 ET | Source: G1 Therapeutics

G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights

G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights
August 07, 2024 06:29 ET | Source: G1 Therapeutics; Pharmacosmos

Pharmacosmos Group to Acquire G1 Therapeutics

Pharmacosmos Group to Acquire G1 Therapeutics
August 01, 2024 18:50 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 25, 2024 11:15 ET | Source: G1 Therapeutics

G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024

G1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024
July 01, 2024 08:00 ET | Source: G1 Therapeutics

G1 Therapeutics Added to the Russell 2000® and 3000® Indexes

G1 Therapeutics Added to the Russell 2000® and 3000® Indexes
June 24, 2024 06:30 ET | Source: G1 Therapeutics

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)

G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negativ
June 05, 2024 07:00 ET | Source: G1 Therapeutics

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 28, 2024 06:30 ET | Source: G1 Therapeutics

Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)

Meaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 ADC

Next Page keyboard_arrow_right